Evidence map›Paper›PMID 42253499›Full record

ArticleParkinson's disease2026

Early Amyloid Formation and Neuroinflammatory Response in a Bigenic Mouse Model Expressing Human α-Synuclein and Aβ.

Radhika Thakore, Markus Aldén, Nadja Gustavsson, Lukas Danielson, Lívia Lins, Jorge Domínguez Sánchez, Ana Rosenthal Arensburg, Agnes Paulus, Iran Augusto Neves da Silva, Valeriia Skoryk and 6 more

Abstract read
In one paragraph

Article in Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Radhika ThakoreMedical Microspectroscopy, Department of Experimental Medical Science, NanoLund, Multipark, Lund University, Lund, Sweden, lu.se.ORCID https://orcid.org/0009-0000-7253-0367
Markus AldénBasal Ganglia Pathophysiology, Department of Experimental Medical Science, Lund University, Lund, Sweden, lu.se.ORCID https://orcid.org/0000-0002-5166-0055
Nadja GustavssonMedical Microspectroscopy, Department of Experimental Medical Science, NanoLund, Multipark, Lund University, Lund, Sweden, lu.se.ORCID https://orcid.org/0000-0002-8588-5420
Lukas DanielsonMedical Microspectroscopy, Department of Experimental Medical Science, NanoLund, Multipark, Lund University, Lund, Sweden, lu.se.ORCID https://orcid.org/0000-0003-3211-7492
Lívia LinsBehavioural Neuroscience Laboratory, Department of Experimental Medical Science, Lund University, Lund, Sweden, lu.se.ORCID https://orcid.org/0000-0003-4229-9867
Jorge Domínguez SánchezMedical Microspectroscopy, Department of Experimental Medical Science, NanoLund, Multipark, Lund University, Lund, Sweden, lu.se.ORCID https://orcid.org/0009-0008-0808-4612
Ana Rosenthal ArensburgMedical Microspectroscopy, Department of Experimental Medical Science, NanoLund, Multipark, Lund University, Lund, Sweden, lu.se.ORCID https://orcid.org/0009-0002-2318-2137
Agnes PaulusMedical Microspectroscopy, Department of Experimental Medical Science, NanoLund, Multipark, Lund University, Lund, Sweden, lu.se.ORCID https://orcid.org/0009-0005-2587-3400
Iran Augusto Neves da SilvaMedical Microspectroscopy, Department of Experimental Medical Science, NanoLund, Multipark, Lund University, Lund, Sweden, lu.se.ORCID https://orcid.org/0000-0002-5084-5429
Valeriia SkorykMedical Microspectroscopy, Department of Experimental Medical Science, NanoLund, Multipark, Lund University, Lund, Sweden, lu.se.ORCID https://orcid.org/0000-0003-0633-6130
Rakez KayedDepartment of Neurology and Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, Texas, USA, utmb.edu.ORCID https://orcid.org/0000-0001-6216-8640
Gunnar K GourasExperimental Dementia Research Unit, Department of Experimental Medical Science, Lund University, Lund, Sweden, lu.se.ORCID https://orcid.org/0000-0002-5500-6325
Tomas DeierborgExperimental Neuroinflammation Laboratory, Department of Experimental Medical Science, Lund University, Lund, Sweden, lu.se.ORCID https://orcid.org/0000-0002-3651-3444
Andreas HeuerBehavioural Neuroscience Laboratory, Department of Experimental Medical Science, Lund University, Lund, Sweden, lu.se.ORCID https://orcid.org/0000-0003-0300-7606
Sabine C KoningsMedical Microspectroscopy, Department of Experimental Medical Science, NanoLund, Multipark, Lund University, Lund, Sweden, lu.se.ORCID https://orcid.org/0000-0003-4008-2779
Oxana KlementievaMedical Microspectroscopy, Department of Experimental Medical Science, NanoLund, Multipark, Lund University, Lund, Sweden, lu.se.ORCID https://orcid.org/0000-0003-1782-050X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein aggregation is a hallmark of several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies. A common feature of these disorders is the misfolding and aggregation of α-synuclein (α-syn) and amyloid-β (Aβ) proteins into amyloid structures, which disrupt cellular homoeostasis and drive disease progression. While Aβ typically forms extracellular deposits and α-syn accumulates in intracellular inclusions, both ultimately contribute to neuronal damage and neurodegeneration. Increasing in vitro evidence suggests that these proteins can interact, altering their structural properties and, in turn, their biological effects; however, the consequences of their co-occurrence in vivo remain unclear. To address this gap, we examined whether α-syn modulates Aβ deposition and associated neuroinflammation at early stages using a physiologically relevant bigenic mouse model coexpressing human α-syn and APP knock-in Aβ. Using combined histological and biochemical analysis, we characterised Aβ load and microglial responses at early time points. Our results indicate that α-syn expression is associated with altered early Aβ deposition and microglial morphology in vivo. Specifically, while early Aβ deposits were detected in both Aβ/α-syn and Aβ-control mice from 2 months of age, at 4 and 6 months, reduced number and size of Aβ microdeposits was observed in the Aβ/α-syn model. The reduction in Aβ load was accompanied by a more ramified microglial morphology consistent with a less activated microglial state. Whether this delayed response reflects protection or impaired immune surveillance remains unclear. Our findings highlight the complexity of indirect Aβ and α-syn interactions and the need for further studies to clarify their functional impact. The newly generated bigenic mice provide a relevant platform to investigate early co-pathology and its role in disease progression.

Indexed as

amyloid microdepositionamyloid-βpeptidesmicrogliaα-synuclein

Identifiers

PMID42253499
PMCPMC13238505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.